U.S. Bancorp Posts Drop in 1Q Profit on Revenue, Provision for Credit Losses Hit
By Sabela Ojea
U.S. Bancorp said first-quarter profit dropped in the latest quarter due to lower revenue and an increase in its provision for credit losses.
The Minneapolis-based parent company of U.S. Bank on Wednesday posted a net income of $1.33 billion, or 78 cents a share, compared with $1.70 billion, or $1.04 a share, for the same period a year earlier. Adjusted earnings were 90 cents, beating analysts expectations of 88 cents.
Revenue dropped 6.4% to $6.72 billion. Analysts polled by FactSet had forecast revenue of $6.71 billion.
The regional lender provisioned increased its provision for credit losses to $553 million from $512 million in the fourth quarter, and $427 million for the same period a year earlier.
U.S. Bancorp ended the quarter with a common equity Tier 1 ratio--a key measure of balance-sheet strength--of 10% from 9.9% as of December 31, 2023.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 17, 2024 07:22 ET (11:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track